New imaging method for evaluating gliomas
Development of Activity MRI (aMRI): Direct Comparison to PET in Human Subjects
This study is testing a new imaging method to see if it can better diagnose and assess brain tumors called gliomas compared to the standard imaging technique.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | OHSU Knight Cancer Institute Academic / other |
| Locations | 1 site (Portland, Oregon) |
| Trial ID | NCT05937776 on ClinicalTrials.gov |
What this trial studies
This observational study aims to compare a novel metabolic imaging approach called aMRI with the standard imaging method, ¹⁸FDG PET, for diagnosing and assessing gliomas. The study will evaluate how the metabolic activity of tumor cells differs from normal brain tissue using these imaging techniques. Patients will receive a radioactive tracer and undergo simultaneous MRI and PET scanning to gather detailed images of their brain. The study will also explore how metabolic parameters change with different types of gliomas and their treatment status.
Who should consider this trial
Good fit: Ideal candidates are adult patients over 18 years old diagnosed with glioma who require MRI and ¹⁸FDG-PET imaging.
Not a fit: Patients without gliomas or those who do not require metabolic imaging will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a more accessible and effective imaging method for diagnosing and monitoring gliomas.
How similar studies have performed: While metabolic imaging is a well-established field, the specific aMRI approach being tested is novel and has not been widely validated in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (greater than 18 years of age) with glioma who require MRI and ¹⁸FDG-PET imaging.
Where this trial is running
Portland, Oregon
- OHSU Knight Cancer Institute — Portland, Oregon, United States (Recruiting)
Study contacts
- Principal investigator: Martin Pike, Ph.D. — OHSU Knight Cancer Institute
- Study coordinator: Martin Pike, Ph.D.
- Email: pikema@ohsu.edu
- Phone: 503-494-2951
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.